Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas [RNA-seq]

ABSTRACT: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas [RNA-seq]

PROVIDER: PRJNA768454 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16195435.fastq.gz	Fastqsanger.gz
	SRR16195436.fastq.gz	Fastqsanger.gz
	SRR16195437.fastq.gz	Fastqsanger.gz
	SRR16195438.fastq.gz	Fastqsanger.gz
	SRR16195439.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Project description:MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

| PRJNA902087 | ENA

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Project description:Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes the peptide MHC (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1000 copies-per-cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting 4 epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.

2023-03-11 | PXD029860 | Pride

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas [RNA-seq]

2022-11-15 | GSE185284 | GEO

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data

2023-03-11 | PXD029884 | Pride

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas.

Project description:Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma-namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), and targeted immunotherapies-may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition (MEKi) alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes in the peptide major histocompatibility molecules (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1,000 copies per cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting four epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.

| S-EPMC9894220 | biostudies-literature

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-15 | GSE218070 | GEO

Translation dysregulation in cancer as a source for targetable antigens.

Project description:Translation dysregulation in cancer as a source for targetable antigens.

| PRJNA1139766 | ENA

Single-cell RNA-seq reveals intratumoral heterogeneity in primary uveal melanomas and discloses new targetable vulnerability

Project description:Lack of specific markers for invasive uveal melanoma cells prevents early diagnosis of metastasis, while no systemic treatment options are available for patients with disseminated uveal melanomas. Intra-tumor heterogeneity has been recognized in numerous cancers as the main cause of metastasis development and therapy resistance. However, in uveal melanomas the specific subpopulations and their biological function which influence tumor behavior remained unknown. Here, using scRNA-seq analysis of six different primary uveal melanomas, we uncovered previously unrecognized intratumor heterogeneity. We localized diverse tumor-associated populations and transcriptional states in primary uveal melanomas. We also unraveled a gene regulatory network underlying a poor prognosis melanoma state. Heterogeneity was demonstrated in uveal melanoma tissue using the RNAscope assay. Thus, single-cell analysis offers an unprecedented view of intratumor heterogeneity in primary uveal melanoma, identified bona fide biomarkers for metastatic cells in the primary tumor, and unravel targetable modules driving metastase formation and growth, with critical implications for prognosis and therapeutic opportunity.

2021-01-25 | GSE138433 | GEO

Dietary antigens influence the antigen presentation pathway of small intestine epithelium

Project description:Dietary antigens influence the antigen presentation pathway of small intestine epithelium

| PRJNA487175 | ENA

Noncoding regions are the main source of targetable tumor-specific antigens

Project description:Noncoding regions are the main source of targetable tumor-specific antigens

| PRJNA525590 | ENA